Comparative Pharmacology
Head-to-head clinical analysis: AZASAN versus CELLCEPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASAN versus CELLCEPT.
AZASAN vs CELLCEPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azathioprine is a purine analog that inhibits purine synthesis, thereby interfering with DNA and RNA synthesis. It is metabolized to 6-mercaptopurine, which inhibits T-cell activation and proliferation, leading to immunosuppression.
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
1-3 mg/kg/day orally once daily or divided twice daily; maximum dose 2.5 mg/kg/day for rheumatoid arthritis; usual dose 50-150 mg/day.
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
None Documented
None Documented
Terminal elimination half-life of azathioprine is approximately 4.5 hours (range 2–6 h), while its active metabolite 6-mercaptopurine has a half-life of 0.5–2 hours. Clinical context: Renal impairment prolongs half-life.
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Renal: 88% as 6-mercaptopurine and metabolites; biliary: <10%
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Category C
Category C
Immunosuppressant
Immunosuppressant